Affinity and specificity of N-methyl-D-aspartate channel blockers affect their ability to disrupt prepulse inhibition of acoustic startle in rats

Psychopharmacology

Volumn 165, Issue 4, 2003, Pages 378-385

  Wiley, Jenny L ^a   Harvey, Sarah A ^a   Balster, Robert L ^a   Nicholson, Katherine L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Dizocilpine; NMDA antagonists; Prepulse inhibition; Startle

Indexed keywords

ALAPROCLATE; AMANTADINE; DESIPRAMINE; DEXTROMETHORPHAN; DEXTRORPHAN; DIZOCILPINE; IBOGAINE; LIGAND; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; ORPHENADRINE CITRATE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY STIMULATION; CONTROLLED STUDY; DRUG DOSE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; RAT STRAIN; RECEPTOR AFFINITY; SENSORIMOTOR FUNCTION; STARTLE REFLEX; STIMULUS RESPONSE;

EID: 0037320246     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1297-6     Document Type: Article

References (65)

1. Backstrom IT, Marcusson JO (1990) High- and low-affinity [3H]desipramine-binding sites in human postmortem brain tissue. Neuropsychobiology 23:68-73
2. Balster RL, Mansbach RS, Shelton KL, Nicholson KL, Grech DM, Wiley JL, Li H, Weber E (1995) Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists. Behav Pharmacol 6:577-589
3. Baron BM, Harrison BL, Kehne JH, Schmidt CJ, Van Giersbergen PLM, White HS, Siegel BW, Senyah Y, McCloskey TC, Fadayel GM, Taylor VL, Murawsky MK, Nyce P, Salituro FG (1997) Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist. Eur J Pharmacol 323:181-192
4. Braff D, Stone C, Calloway E, Geyer M, Glick I, Bali L (1978) Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15:339-343
5. Bresink I, Danysz W, Parsons CG, Mutschler E (1995) Different binding affinities of NMDA receptor channel blockers in various brain regions - indication of NMDA receptor heterogeneity. Neuropharmacology 34:533-540
6. Bristow LJ, Landon L, Saywell KL, Tricklebank MD (1995) The glycine/NMDA receptor antagonist L-701,324 reverses isolation-induced deficits in prepulse inhibition in the rat. Psychopharmacology 118:230-232
7. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
8. Danysz W, Parsons CG, Bresink I, Quack G (1995) Glutamate in CNS disorders: a revived target for drug development? Drug News Perspect 5:261-277
9. Depoortere R, Perrault G, Sanger DJ (1999) Prepulse inhibition of the startle reflex in rats: effects of compounds acting at various sites on the NMDA receptor complex. Behav Pharmacol 10:51-62
10. Duncan EJ, Madonick SH, Parwani A, Angrist B, Rajan R, Chakravorty S, Efferen T, Szilagyi S, Stephanides M, Chappel PB, Gonzenbach S, Ko GN, Rotrosen JP (2001) Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 25:72-83
11. El-Fakahany E, Richelson E (1983) Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol 78:97-102
12. Fisher A, Starr MS (2000) Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain. Brain Res 868:268-274
13. France CP, Snyder AM, Woods JH (1989) Analgesic effects of phencyclidine-like drugs in rhesus monkeys. J Pharmacol Exp Ther 250:197-201
14. 3H] dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel. Mol Pharmacol 41:134-146
15. Furuya Y, Ogura H (1997) Competitive NMDA and strychnine-insensitive glycine-site antagonists disrupt prepulse inhibition. Pharmacol Biochem Behav 57:909-913
16. Geter-Douglass B, Witkin JM (1999) Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice. Psychopharmacology 146:280-289
17. Geyer MA, Swerdlow NR, Mansbach RS, Braff DL (1990) Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 25:485-498
18. Grant KA, Colombo G, Grant J, Rogawski MA (1996) Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology 35:1709-1719
19. Harkin A, Morris K, Kelly JP, O'Donnell JM, Leonard BE (2001) Modulation of MK-801-induced behaviour by noradrenergic agents in mice. Psychopharmacology 154:177-188
20. Helsley S, Filipink RA, Bowen WD, Rabin RA, Winter JC (1998) The effects of sigma, PCP, and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus. Pharmacol Biochem Behav 59:495-503
21. Herman BH, Vocci F, Bridge P (1995) The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Neuropsychopharmacology 13:269-293
22. Hoffman HS, Ison JR (1980) Reflex modification in the domain of startle. I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev 87:175-189
23. Holtzman SG (1994) Discriminative stimulus effects of dextromethorphan in the rat. Psychopharmacology 116:249-254
24. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308
25. Johansson C, Jackson DM, Svensson L (1994) The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat. Psychopharmacology 116:437-442
26. Jones HE, Li H, Balster RL (1998) Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys. Pharmacol Biochem Behav 59:413-418
27. Kehne JH, Padich RA, McCloskey TC, Taylor VL, Schmidt CJ (1996) 5-HT modulation of auditory and visual sensorimotor gating. I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats. Psychopharmacology 124:95-106
28. Keith VA, Mansbach RS, Geyer MA (1991) Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of acoustic startle. Biol Psychiatry 30:557-566
29. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P (1995) Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm 102:237-246
30. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 51:199-214
31. Lindberg UH, Thornberg SO, Bengtsson S, Renyi AL, Ross SB, Ogren SO (1978) Inhibition of neuronal monoamine uptake 2. Selective inhibition of 5-hydroxytryptamine uptake by alpha-amino esters of phenetyl alcohols. J Med Chem 21:498-565
32. Mansbach RS (1991) Effects of NMDA receptor ligands on sensorimotor gating in the rat. Eur J Pharmacol 202:61-66
33. Mansbach RS, Geyer MA (1989) Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2:299-308
34. Mansbach RS, Geyer MA (1991) Parametric determinants in prestimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology 105:162-168
35. Mansbach RS, Geyer MA, Braff DL (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology 94:507-514
36. Martinez DL, Geyer MA (1997) Characterization of the disruptions of prepulse inhibition and habituation of startle induced by alpha-ethyltryptamine. Neuropsychopharmacology 16:246-255
37. Murray TF, Leid ME (1984) Interaction of dextrorotatory opioids with phencyclidine recognition sites in rat brain membranes. Life Sci 34:1899-1911
38. National Research Council (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington
39. Nicholson KL, Jones HE, Balster RL (1998) Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine. Behav Pharmacol 9:231-243
40. Nicholson KL, Hayes BA, Balster RL (1999) Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology 146:49-59
41. Ouagazzal AM, Jenck F, Moreau JL (2001) Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? Psychopharmacology 156:273-283
42. Parsons CG, Danysz W, Quack G (1999) Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38:735-767
43. Patat A, Molinier P, Hergueta T, Brohier S, Zieleniuk I, Danjou P, Warot D, Puech A (1994) Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist. Int Clin Psychopharmacol 9:155-162
44. Popik P, Layer RT, Skolnick P (1994) The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex. Psychopharmacology 114:672-674
45. Ramachander G, Williams FD, Emele JF (1977) Determination of dextrorphan in plasma and evaluation of bioavailability of dextromethorphan hydrobromide in humans. J Pharmacol Sci 66:1047-1048
46. Reynolds IJ, Miller RJ (1988) Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Br J Pharmacol 95:95-102
47. Riekkinen P Jr, Jakala P, Sirvio J, Riekkinen P (1991) The effects of increased serotonergic and decreased cholinergic activities on spatial navigation performance in rats. Pharmacol Biochem Behav 39:25-29
48. Rockstroh S, Emre M, Tarral A, Pokorny R (1996) Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans. Psychopharmacology 124:261-266
49. Rogawski MA (1993) Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 14:325-331
50. Rogawski MA (2000) Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents toward an understanding of their favourable tolerability. Amino Acids 19:133-149
51. Sanger DJ, Terry P, Katz JL (1992) Memantine has phencyclidine-like but not cocaine-like discriminative stimulus effects in rats. Behav Pharmacol 3:265-268
52. Schadel M, Wu D, Otton SV, Kalow W, Sellers EM (1995) Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol 15:263-269
53. Steinberg GK, Kunis D, DeLaPaz R, Poljak A (1993) Neuroprotection following focal cerebral ischemia with the NMDA antagonist dextromethorphan, has a favourable dose response profile. Neurol Res 15:174-180
54. Sveinbjornsdottir S, Sander JWAS, Upton D, Thompson PJ, Patsalos PN, Hirt D, Emre M, Lowe D, Duncan JS (1993) The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 16:165-174
55. Svensson BE, Ross SB (1995) Alaproclate interaction with the NMDA receptor ion channel complex as studied by its effects on [3H]-MK801 binding. Soc Neurosci Abstr 21:352
56. Svensson BE, Werkman TR, Rogawski MA (1994) Alaproclate effects on voltage-dependent K+ channels and NMDA receptors: studies in cultured rat hippocampal neurons and fibroblast cells transformed with Kvl.2 K+ channel cDNA. Neuropharmacology 33:795-804
57. Syvälahti EK, Kunelius R, Lauren L (1988) Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol Toxicol 62:90-94
58. Swerdlow NR, Taaid N, Oostwegel JL, Randolph E, Geyer MA (1998) Towards a cross-species pharmacology of sensorimotor gating: effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats. Behav Pharmacol 9:389-396
59. Tortella FC, Musacchio JM (1986) Dextromethorphan and carbetapentane: centrally acting non-opioid antitussive agents with novel anticonvulsant properties. Brain Res 383:314-318
60. Van Berckel BN, Oranje B, VanRee JM, Verbaten MN, Kahn RS (1998) The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology 137:271-281
61. Wedzony K, Golembiowska K, Zazula M (1994) Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats. Naunyn Schmiedebergs Arch Pharmacol 350:555-562
62. Wiley JL (1998) Nitric oxide synthase inhibitors attenuate phencyclidine-induced disruption of prepulse inhibition. Neuropsychopharmacology 19:86-94
63. Wilkinson A, Courtney M, Westlind-Danielsson A, Hallnemo G, Akerman KEO (1994) Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow. J Pharmacol Exp Ther 271:1314-1319
64. 3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes. J Neurochem 50:274-278
65. Wu D, Otton SV, Kalow W, Sellers EM (1995) Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat. J Pharmacol Exp Ther 274:1431-1437